翔宇医疗(688626) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 reached CNY 143,153,527.80, representing a year-on-year increase of 68.25%[4] - Net profit attributable to shareholders was CNY 37,812,580.60, marking a significant increase of 298.99% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was CNY 32,553,857.41, reflecting a substantial growth of 549.98% year-on-year[4] - Basic and diluted earnings per share were both CNY 0.24, which is a 300% increase from the same period last year[4] - The net profit for Q1 2023 reached CNY 38,592,209.22, up from CNY 8,332,824.99 in Q1 2022, marking a growth of approximately 363.5%[21] - The earnings per share for Q1 2023 were CNY 0.24, compared to CNY 0.06 in Q1 2022, reflecting a 300% increase[22] Cash Flow - The net cash flow from operating activities amounted to CNY 36,450,103.71, an increase of 251.84% compared to the previous year[4] - In Q1 2023, the company generated operating cash inflow of CNY 183,353,703.59, a 72.7% increase from CNY 106,200,506.73 in Q1 2022[25] - The net cash flow from operating activities was CNY 36,450,103.71, compared to a negative cash flow of CNY -24,005,795.51 in the same period last year[25] - The company reported a total cash and cash equivalents balance of CNY 832,260,520.32 as of March 31, 2023, up from CNY 749,152,830.61 at the end of 2022[26] - Investment activities generated a net cash inflow of CNY 27,421,758.09, a significant improvement from a net outflow of CNY -52,946,795.92 in Q1 2022[26] - The company's cash inflow from sales of goods and services was CNY 162,957,664.29, up from CNY 94,386,927.88 in Q1 2022, representing a 72.9% increase[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,427,280,318.30, reflecting a 2.50% increase from the end of the previous year[5] - The total current assets decreased slightly to RMB 1,655,063,836.09 from RMB 1,668,379,570.59, indicating a decline of about 0.8%[17] - The company’s total liabilities increased, with short-term borrowings rising to CNY 58,000,000.00 from CNY 3,000,000.00 at the end of 2022[29] - The total liabilities for Q1 2023 were CNY 452,016,292.46, compared to CNY 428,219,732.64 in Q1 2022, which is an increase of approximately 5.5%[19] - The total assets as of Q1 2023 amounted to CNY 2,427,280,318.30, up from CNY 2,368,078,429.22 in the previous year, showing an increase of about 2.5%[19] Research and Development - Research and development expenses totaled CNY 21,608,723.98, accounting for 15.09% of operating revenue, a decrease of 6.54 percentage points year-on-year[5] - Research and development expenses for Q1 2023 were CNY 21,608,723.98, compared to CNY 18,405,732.79 in Q1 2022, indicating an increase of approximately 17.5%[21] - The company achieved 16 new medical device registrations and a total of 257 registrations, alongside 67 new patents, bringing the cumulative total to 1,318 patents[13] - The company reported a total of 83 new intellectual property rights in the current year, contributing to a cumulative total of 1,596 rights[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,994[9] - The total equity attributable to shareholders of the parent company was CNY 1,962,218,182.98, compared to CNY 1,927,592,482.34 in the previous year, showing an increase of approximately 1.8%[19] Inventory and Investments - The company’s inventory decreased to RMB 217,798,316.59 from RMB 222,820,180.68, reflecting a reduction of approximately 2.3%[17] - The company’s long-term equity investments decreased slightly to RMB 16,717,451.07 from RMB 17,086,737.70, a decline of about 2.2%[17] - The company’s fixed assets decreased to RMB 91,637,608.59 from RMB 93,870,801.11, a decline of about 2.4%[17] - The company’s construction in progress increased to RMB 385,358,997.23 from RMB 314,093,717.93, indicating a growth of approximately 22.7%[17] Recognition and Achievements - The company was recognized as a leading enterprise in intellectual property in Henan Province and approved as a model enterprise for industry-university-research cooperation in China[13]